Novartis AG (NVS)
| Market Cap | 223.50B |
| Revenue (ttm) | 53.22B |
| Net Income (ttm) | 12.86B |
| Shares Out | 1.96B |
| EPS (ttm) | 6.38 |
| PE Ratio | 17.76 |
| Forward PE | 12.76 |
| Dividend | $3.99 (3.53%) |
| Ex-Dividend Date | Mar 12, 2025 |
| Volume | 881,071 |
| Open | 114.14 |
| Previous Close | 114.29 |
| Day's Range | 112.71 - 114.14 |
| 52-Week Range | 96.06 - 120.92 |
| Beta | 0.53 |
| Analysts | Hold |
| Price Target | 123.67 (+9.13%) |
| Earnings Date | Apr 29, 2025 |
About NVS
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $123.67, which is an increase of 9.13% from the latest price.
News
BioNTech says Novartis executive Zapata-Gomez to become CFO
German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.
Final Trade: NVS, XLU and SMMT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed
Novartis' Q1 2025 results validate our investment thesis. They showcase double-digit sales growth and robust margins, reinforcing our overweight position. Novartis announced a $23 billion US investmen...
Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis
In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure...
Novartis to Acquire Regulus in $1.7 Billion Deal
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutic...
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximate...
We have put ourselves in the right position to manage tariffs: Novartis CEO
Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings.
Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry
Vasant Narasimhan, Novartis CEO, discusses the impact of potential tariffs.
Novartis AG (NVS) Q1 2025 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - CEO Harry Kirsch - CFO Conference Ca...
Novartis CEO on earnings: Launch drivers like breast cancer, MS medicines are performing really well
Vasant Narasimhan, Novartis CEO, joins 'Money Movers' to discuss the company's quarterly earnings results.
Pharma firms maastraz
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
Novartis posts better-than-expected first-quarter sales, raises full-year guidance
Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year guidance. Net sales were up 15% on a constant currency basis to $13.2 billion, ...
Novartis Lifts Guidance After Profit, Sales Top Views
Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs.
Novartis more upbeat on 2025 guidance after strong Q1 momentum
Novartis on Tuesday issued a more optimistic full-year earnings guidance, citing strong growth of drugs such as Kisqali, Kesimpta and Leqvio during the first quarter.
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on...
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs
Swiss pharmaceutical giant Novartis (NVS) said it plans to invest $23 billion in the construction and expansion of 10 U.S. facilities, as drugmakers brace for potential tariffs from the Trump administ...